Juan Batlle, MD, provides 2-year data from a recent international collaborative study on the MicroShunt (Santen, distributed by Glaukos). In total, three centers participated and 125 cases were included. The investigators showed reduction in IOP, by 8.9 mm Hg, and in the number of medications patients required postoperatively, from 2.2 to 0.5.
Glaukos Corporation • Intraocular Pressure, IOP • Santen
11 / 20 Series: ASCRS 2019